ADAGRASIB

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C32H35ClFN7O2
Molecular Weight	604.117
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=C5C(Cl)=CC=CC5=CC=C4)C(=N2)N6CCN([C@@H](CC#N)C6)C(=O)C(F)=C

InChI

InChIKey=PEMUGDMSUDYLHU-ZEQRLZLVSA-N

InChI=1S/C32H35ClFN7O2/c1-21(34)31(42)41-17-16-40(18-23(41)11-13-35)30-25-12-15-39(28-10-4-7-22-6-3-9-26(33)29(22)28)19-27(25)36-32(37-30)43-20-24-8-5-14-38(24)2/h3-4,6-7,9-10,23-24H,1,5,8,11-12,14-20H2,2H3/t23-,24-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C32H35ClFN7O2
Molecular Weight	604.117
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340s000lbl.pdf|https://pubmed.ncbi.nlm.nih.gov/36763320

Adagrasib (KRAZATI™) is an orally available, potent, small molecule inhibitor of KRAS G12C mutant isoform being developed by Mirati Therapeutics for the treatment of solid tumours harbouring KRAS G12C oncogenic driver mutation, including non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). Adagrasib is an irreversible inhibitor of KRAS G12C that covalently binds to the mutant cysteine in KRAS G12C and locks the mutant KRAS protein in its inactive state that prevents downstream signaling without affecting wild-type KRAS protein. Adagrasib inhibits tumor cell growth and viability in cells harboring KRAS G12C mutations and results in tumor regression in KRAS G12C-mutated tumor xenograft models with minimal off-target activity. In December 2022, adagrasib received its first approval in the USA for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic NSCLC (as determined by an FDA approved test) who have received ≥ 1 prior systemic therapy. It was approved under accelerated approval based on objective response rate and duration of response, and its continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial(s). The drug is under regulatory review for NSCLC in the European Union and is in development for CRC in the US. Clinical studies of adagrasib in solid tumours, including CRC, are underway in several countries.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
GTPase KRas 5 Target ID: CHEMBL2189121 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340s000lbl.pdf\|https://pubmed.ncbi.nlm.nih.gov/32250617	Inhibitor 8504		14.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer 2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340s000lbl.pdf	Primary		Approved 8583	KRAZATI Approved Use KRAZATI is an inhibitor of the RAS GTPase family indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy. Launch Date 2022

C_max

Value	Dose	Co-administered	Analyte	Population
984 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35167329/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		ADAGRASIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED
3253 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35167329/	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		ADAGRASIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
37139 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35167329/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		ADAGRASIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED
31600 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35167329/	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		ADAGRASIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
23 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35167329/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		ADAGRASIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
2% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35167329/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		ADAGRASIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED
2% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35167329/	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		ADAGRASIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
600 mg 2 times / day steady, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf	Disc. AE: Gastrointestinal disorders, Pyrexia... AEs leading to discontinuation/dose reduction: Gastrointestinal disorders (1 patient) Pyrexia (1 patient) Pneumonia (1 patient) Encephalitis (1 patient) Lung Infection (1 patient) Sepsis (1 patient) Alanine aminotransferase increase (1 patient) Aspartate aminotransferase increase (1 patient) Ejection fraction decrease (1 patient) Muscle weakness (1 patient) Malignant neoplasm progression (2 patients) Cerebrovascular accident (1 patient) Respiratory disorders (5 patients) Hypotension (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf

AEs

AE	Significance	Dose	Population
Alanine aminotransferase increase	1 patient Disc. AE	600 mg 2 times / day steady, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf
Aspartate aminotransferase increase	1 patient Disc. AE	600 mg 2 times / day steady, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf
Cerebrovascular accident	1 patient Disc. AE	600 mg 2 times / day steady, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf
Ejection fraction decrease	1 patient Disc. AE	600 mg 2 times / day steady, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf
Encephalitis	1 patient Disc. AE	600 mg 2 times / day steady, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf
Gastrointestinal disorders	1 patient Disc. AE	600 mg 2 times / day steady, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf
Hypotension	1 patient Disc. AE	600 mg 2 times / day steady, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf
Lung Infection	1 patient Disc. AE	600 mg 2 times / day steady, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf
Muscle weakness	1 patient Disc. AE	600 mg 2 times / day steady, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf
Pneumonia	1 patient Disc. AE	600 mg 2 times / day steady, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf
Pyrexia	1 patient Disc. AE	600 mg 2 times / day steady, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf
Sepsis	1 patient Disc. AE	600 mg 2 times / day steady, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf
Malignant neoplasm progression	2 patients Disc. AE	600 mg 2 times / day steady, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf
Respiratory disorders	5 patients Disc. AE	600 mg 2 times / day steady, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 substrate 1946	substrate 1193 inhibitor 2438	substrate 1388 inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2B6 926 P-gp 1741 BCRP 910 MATE1 415	BCRP 697 CYP1A2 1197 CYP2J2 71 CYP2C8 810 CYP2B6 776 CYP3A5 446 P-gp 2052

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf Page: 57.0	likely
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf Page: 57.0	likely
MATE1 416	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf Page: 57.0	likely
BCRP 985	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf Page: 57.0	likely	weak (co-administration study) Comment: 400mg BID increased Rosuvastatin (5mg SD) Cmax and AUC by 1.06-fold and 1.35-fold. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf Page: 57.0
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf Page: 57.0	likely	weak (co-administration study) Comment: 600mg SD increased Digoxin (0.25mg SD) Cmax and AUC by 1.05-fold and 1.38-fold. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf Page: 57.0
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf Page: 57 \| 98	likely	yes (co-administration study) Comment: 600mg SD increased Warfarin (10mg SD) Cmax and AUC by 1.32-fold and 1.62-fold. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf Page: 57 \| 98
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf Page: 57 \| 99	likely	yes (co-administration study) Comment: 400mg BID increased Dextromethorphan (30mg SD) Cmax and AUC by 1.90-fold and 1.73-fold. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf Page: 57 \| 99

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf#page=57 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf#page=89 \| \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf#page=92 Page: 14.0	major	yes (co-administration study) Comment: Multiple doses of Itraconazole (200mg QD) increased Cmax and AUC (200mg SD) by 2.4-fold and 4-fold Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf#page=57 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf#page=89 \| \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf#page=92 Page: 14.0
CYP1A2 1197	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf#page=57 Page: 14.0	minor
CYP2B6 776	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf#page=57 Page: 14.0	minor
CYP2C8 810	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf#page=57 Page: 14.0	minor
CYP2C9 1193	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf#page=57 Page: 14.0	minor
CYP2D6 1388	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf#page=57 Page: 14.0	minor
CYP2J2 71	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf Page: 96.0	minor
CYP3A5 446	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf Page: 96.0	minor
BCRP 697	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf Page: 57.0	yes
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf Page: 57.0	yes

PubMed

Title	Date	PubMed
Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS(G12C) Mutation.	2022 Jul 14	35658005

Patents

Sample Use Guides

In Vivo Use Guide

Recommended dosage: 600 mg orally twice daily.

Route of Administration: Oral

In Vitro Use Guide

MRTX849 potently inhibits cell growth in the vast majority of KRASG12C-mutant cancer cell lines with IC50 values ranging between 10 nM and 973 nM in the 2D format and between 0.2 nM and 1042 nM in the 3D format.

Substance Class	Chemical Created by `admin` on `Tue Apr 01 22:51:43 GMT 2025` Edited by `admin` on `Tue Apr 01 22:51:43 GMT 2025`
Record UNII	8EOO6HQF8Y
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ADAGRASIB

Official Name

English

KRAZATI

Preferred Name

English

2-PIPERAZINEACETONITRILE, 4-(7-(8-CHLORO-1-NAPHTHALENYL)-5,6,7,8-TETRAHYDRO-2-(((2S)-1-METHYL-2-PYRROLIDINYL)METHOXY)PYRIDO(3,4-D)PYRIMIDIN-4-YL)-1-(2-FLUORO-1-OXO-2-PROPEN-1-YL)-, (2S)-

Systematic Name

English

MRTX-849

Code

English

adagrasib [INN]

Common Name

English

KRAS G12C INHIBITOR MRTX849

Common Name

English

ADAGRASIB [USAN]

Common Name

English

Adagrasib [WHO-DD]

Common Name

English

((2S)-4-(7-(8-CHLORONAPHTHALEN-1-YL)-2-(((2S)-1- METHYLPYRROLIDIN-2-YL)METHOXY)-5,6,7,8- TETRAHYDROPYRIDO(3,4-D)PYRIMIDIN-4-YL)-1-(2-FLUOROPROP2-ENOYL)PIPERAZIN-2-YL)ACETONITRILE

Systematic Name

English

MRTX849

Code

English

Classification Tree Code System Code

FDA ORPHAN DRUG

756320